Dr. Jamile Shammo, an expert on acute myeloid leukemia (AML), describes how common treatment failure and relapse is in AML. Unfortunately, relapse is common in AML. About half of people who go into remission will have a relapse of their leukemia. Treatment failure in the form of primary resistance to chemotherapy is less common in people under 60. She explains that in people under 60, about 35 percent experience treatment failure. In people over 60, treatment failure may be close to 50 percent. She also explains that the majority of relapses occur within two to three years of initial treatment.

• Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.